# CellOrigin Biotech (Hangzhou) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellorigin-biotech-hangzhou-co

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.cellorigin.net
- Total disclosed funding: $16M
- Latest round: Series B (Feb 16, 2022)
- Investors on record: 5

## About

Based in Hangzhou, China and established in 2018, CellOrigin Biotech (Hangzhou) Co., Ltd. is a biotech company that focuses on the research and development of genetically engineered pluripotent stem cells to genetically engineered pluripotent stem cells (iPSC) derived immune cell therapies. Jin Zhang, the founder of the company, used to be a scientist at Amgen before he established the company. The company has set up R&D center and production base in Hangzhou. The team members graduated from Harvard University, Zhejiang University, Scripps Research Institute and domestic pharmaceutical companies. CellOrigin Biotech (Hangzhou) Co., Ltd. has obtained core patents internationally and domestically. In September 2023, it raised series C funding.

The company engages in the research and development of iPSC-derived innate immune cell therapies. It has established a clinical-grade iPSC cell bank. The company has established three major technology platforms: a clinical-level iPSC cell bank, a clone-engineered iPSC technology platform, and an iPSC targeted and efficient differentiation immune cell technology platform. It also has drug development pipelines such as CAR-Mac MB01 and CAR-Mac MB02.

## Funding rounds

- Series B, Feb 16, 2022, $16M — Efung Capital, Yinxinggu Capital, Shanhai Capital, Jifeng Ventures
- Angel, Apr 29, 2019 — Shulan Junjie Capital

## Investors

- Shulan Junjie Capital (https://capitalatlas.ai/funds/shulan-junjie-capital) — Angel
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Yinxinggu Capital (https://capitalatlas.ai/funds/yinxinggu-capital) — Series B
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series B
- Jifeng Ventures (https://capitalatlas.ai/funds/jifeng-ventures) — Series B